Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study

PURPOSE: The treatment of chronic lymphocytic leukemia (CLL) has been revolutionized by targeted therapies that either inhibit proliferation (ibrutinib) or reactivate apoptosis (venetoclax). Both significantly improve survival in CLL and replace chemoimmunotherapy for many patients. However, individ...

Descripción completa

Detalles Bibliográficos
Autores principales: Hillmen, Peter, Rawstron, Andy C., Brock, Kristian, Muñoz-Vicente, Samuel, Yates, Francesca J., Bishop, Rebecca, Boucher, Rebecca, MacDonald, Donald, Fegan, Christopher, McCaig, Alison, Schuh, Anna, Pettitt, Andrew, Gribben, John G., Patten, Piers E.M., Devereux, Stephen, Bloor, Adrian, Fox, Christopher P., Forconi, Francesco, Munir, Talha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2019
Materias:
RAPID COMMUNICATION
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6879312/
https://www.ncbi.nlm.nih.gov/pubmed/31295041
http://dx.doi.org/10.1200/JCO.19.00894

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6879312/
https://www.ncbi.nlm.nih.gov/pubmed/31295041
http://dx.doi.org/10.1200/JCO.19.00894

Ejemplares similares